Cymabay Therapeutics Inc (NASDAQ:CBAY) traded with a subtraction of -$0.19 to close at $15.38on Friday, a downside of -1.22 percent. An average of 1,838,651 shares of common stock have been traded in the last five days. There was a gain of $0.66 in the past week, and it reached a new high 50 times over the past 12 months. The last 20 days have seen an average of 3,158,593 shares traded, while the 50-day average volume stands at 2,255,905.
CBAY stock has increased by 11.61% in the last month. The company shares reached their 1-month lowest point of $13.20 on 09/07/23. With the stock rallying to its 52-week high on 09/12/23, shares of the company touched a low of $3.15 and a high of $18.20 in 52 weeks. It has reached a new high 35 times so far this year and achieved 145.30% or $9.10 in price. In spite of this, the price is down -15.49% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CBAY stock investors should be aware that Cymabay Therapeutics Inc (CBAY) stock had its last reported insider trading activity 11 days ago on Sep 18. In this transaction, the insider spent $352,733. General Counsel, Quinlan Paul T, disposed of 53,000 shares at a price of $16.87 on Sep 15. The insider now owns more than $894,141 worth of shares. Prior to that, President of R&D McWherter Charles went on to Sale 21,746 shares at $11.47 each on Aug 18. An amount of $249,359 was transacted.
Valuation Metrics
Cymabay Therapeutics Inc (CBAY) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is 0.31. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 48.66, the price-to-book (PB) ratio at 13.88.
Financial Health
The quick ratio of Cymabay Therapeutics Inc for the three months ended June 29 was 12.52, and the current ratio was 12.52, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.92 and a total debt to equity ratio of 0.92 for the quarter ending June 29. Its gross profit as reported stood at $14.91 million compared to revenue of $93.11 million.
Earnings Surprise
The company posted a net income of -$0.81 million in the quarter, while revenues of -$28.78 million were shrunk -3244.44%. The analyst consensus anticipated Cymabay Therapeutics Inc’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.01, a 95.00% surprise. For the quarter, EBITDA amounted to -$1.88 million. Shareholders own equity worth $98.15 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Cymabay Therapeutics Inc (CBAY) price momentum. RSI 9-day as of the close on 28 September was 54.04%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.64%.
As of today, CBAY’s price is $15.03 +4.52% or $0.66 from its 5-day moving average. CBAY is currently trading +11.82% higher than its 20-day SMA and +50.88% higher than its 100-day SMA. However, the stock’s current price level is +36.42% above the SMA50 and +279.63% above the SMA200.
The stochastic %K and %D were 30.37% and 29.16%, respectively, and the average true range (ATR) was 0.84. With the 14-day stochastic at 31.27% and the average true range at 0.86, the RSI (14) stands at 55.40%. The stock has reached 0.39 on the 9-day MACD Oscillator while the 14-day reading was at -0.26.
Analyst Ratings
UBS launched coverage on Cymabay Therapeutics Inc (NASDAQ: CBAY) in its analyst report released on August 14, 2023. The firm assigned the stock a Buy rating.
